Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2016 11:01 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics Announces Publication in Nature Medicine Demonstrating that Targeting Tumor Oxidative Stress with AEB3103 Suppresses Cancer Growth in Preclinical Models

AUSTIN, Texas, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
November 09, 2016 08:00 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results

AUSTIN, Texas, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
November 08, 2016 08:00 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors

AUSTIN, Texas, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
November 03, 2016 09:01 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics to Present New Data on AEB3103 at American Society of Hematology (ASH) 58th Annual Meeting

AUSTIN, Texas, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
September 15, 2016 08:00 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics Doses First Patients in Phase 1 Trial of AEB1102 for the Treatment of Arginase I Deficiency

AUSTIN, Texas, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
September 07, 2016 08:00 ET | Source: Aeglea Biotherapeutics

Aeglea BioTherapeutics Appoints Leading Experts to Inaugural Scientific Advisory Board

AUSTIN, Texas, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
September 01, 2016 08:00 ET | Source: Aeglea Biotherapeutics

Aeglea BioTherapeutics to Present at the 2016 Wells Fargo Healthcare Conference

AUSTIN, Texas, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
August 29, 2016 08:00 ET | Source: Aeglea Biotherapeutics

Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies

AUSTIN, Texas, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
August 09, 2016 06:00 ET | Source: Aeglea Biotherapeutics

Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results

AUSTIN, Texas, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
July 18, 2016 08:00 ET | Source: Aeglea Biotherapeutics

Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer

--EMA Issued a Positive Opinion for Orphan Drug Designation for AEB1102-- --Initiated Two Phase 1 Clinical Trials of AEB1102 for Treatment of Hyperargininaemia and Hematological Malignancies-- ...

keyboard_arrow_left Previous Page